文献速递乳腺癌

6基因OncoMasTR检测在激素受体阳性HER2阴性早期乳腺癌中的预后价值:与标准临床病理因素对比

Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
PubMed 文献 · Eur J Cancer · 2021-06-02

该研究基于404例爱尔兰女性乳腺癌样本,评估6基因分子评分OMm和复合风险评分OM的预后性能,并与Oncotype DX复发评分、Ki67、诺丁汉预后指数和临床风险分类进行患者内比较。结果显示OMm和OM对远处无复发生存和浸润性疾病无生存具有显著预后价值,且提供额外预后信息,OM在高风险分类中更准确识别远处复发患者。

要点

  • OMm和OM对DRFS和IDFS均显著预后,C指数分别为0.84和0.85。
  • OMm和OM为所有评估工具提供显著额外预后信息(LRS P≤0.002)。
  • OM比其他工具更准确地将远处复发患者归入高风险类别。

核心结论

  • OncoMasTR评分对激素受体阳性HER2阴性早期乳腺癌的DRFS和IDFS具有显著预后价值,并提供额外预后信息。
  • OM是识别远处复发最准确的风险分类工具,6基因签名可提高预后可靠性。

研究设计与样本

  • 独立转化研究,纳入404例爱尔兰女性乳腺癌患者,来自11家医院,曾参与TAILORx试验。
  • 通过RT-qPCR测量基因表达计算OMm和OM,采用Cox比例风险模型和Kaplan-Meier分析评估预后价值。

主要发现

  • OMm和OM对DRFS的LRS P<0.001,C指数分别为0.84和0.85。
  • OMm和OM为所有其他评估工具/因素提供显著额外预后信息(所有LRS P≤0.002)。
  • OM正确分类更多远处复发患者至高危类别,IDFS结果类似。

关键数值与推荐

  • OMm和OM对DRFS的C指数分别为0.84和0.85,LRS P<0.001。
  • OMm和OM为其他工具提供额外预后信息的LRS P≤0.002。
  • OM在高风险分类中识别远处复发患者优于其他风险分类工具。

临床怎么用

  • 6基因OncoMasTR评分可用于激素受体阳性HER2阴性早期乳腺癌的风险分层,辅助治疗决策优化。
  • OM可能提高高风险患者识别准确性,补充常规临床病理因素。

局限性

  • 样本仅限爱尔兰女性,可能限制普遍性。
  • 研究为转化研究,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of the study was to assess the prognostic performance of a 6-gene molecular score (OncoMasTR Molecular Score [OMm]) and a composite risk score (OncoMasTR Risk Score [OM]) and to conduct a within-patient comparison against four routinely used molecular and clinicopathological risk assessment tools: Oncotype DX Recurrence Score, Ki67, Nottingham Prognostic Index and Clinical Risk Category, based on the modified Adjuvant! Online definition and three risk factors: patient age, tumour size and grade. METHODS: Biospecimens and clinicopathological information for 404 Irish women also previously enrolled in the Trial Assigning Individualized Options for Treatment [Rx] were provided by 11 participating hospitals, as the primary objective of an independent translational study. Gene expression measured via RT-qPCR was used to calculate OMm and OM. The prognostic value for distant recurrence-free survival (DRFS) and invasive disease-free survival (IDFS) was assessed using Cox proportional hazards models and Kaplan-Meier analysis. All statistical tests were two-sided ones. RESULTS: OMm and OM (both with likelihood ratio statistic [LRS] P < 0.001; C indexes = 0.84 and 0.85, respectively) were more prognostic for DRFS and provided significant additional prognostic information to all other assessment tools/factors assessed (all LRS P ≤ 0.002). In addition, the OM correctly classified more patients with distant recurrences (DRs) into the high-risk category than other risk classification tools. Similar results were observed for IDFS. DISCUSSION: Both OncoMasTR scores were significantly prognostic for DRFS and IDFS and provided additional prognostic information to the molecular and clinicopathological risk factors/tools assessed. OM was also the most accurate risk classification tool for identifying DR. A concise 6-gene signature with superior risk stratification was shown to increase prognosis reliability, which may help clinicians optimise treatment decisions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lynch SM, Russell NM, Barron S, et al. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. Eur J Cancer. 2021. PMID: 34090143. doi:10.1016/j.ejca.2021.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。